Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2009 2
2010 2
2011 1
2012 4
2013 3
2014 2
2015 4
2016 4
2017 4
2018 7
2019 1
2020 2
2021 3
2022 6
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts.
Eigentler A, Handle F, Schanung S, Degen A, Hackl H, Erb HHH, Fotakis G, Hoefer J, Ploner C, Jöhrer K, Heidegger I, Pircher A, Klotz W, Herold M, Schäfer G, Culig Z, Puhr M. Eigentler A, et al. Among authors: puhr m. Oncogene. 2024 Jan;43(4):235-247. doi: 10.1038/s41388-023-02901-5. Epub 2023 Nov 29. Oncogene. 2024. PMID: 38017134 Free PMC article.
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
Csizmarik A, Nagy N, Keresztes D, Váradi M, Bracht T, Sitek B, Witzke K, Puhr M, Tornyi I, Lázár J, Takács L, Kramer G, Sevcenco S, Maj-Hes A, Hadaschik B, Nyirády P, Szarvas T. Csizmarik A, et al. Among authors: puhr m. Prostate Cancer Prostatic Dis. 2023 Aug 26. doi: 10.1038/s41391-023-00713-y. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37634036
Therapy-Induced Stromal Senescence Promoting Aggressiveness of Prostate and Ovarian Cancer.
Pardella E, Pranzini E, Nesi I, Parri M, Spatafora P, Torre E, Muccilli A, Castiglione F, Fambrini M, Sorbi F, Cirri P, Caselli A, Puhr M, Klocker H, Serni S, Raugei G, Magherini F, Taddei ML. Pardella E, et al. Among authors: puhr m. Cells. 2022 Dec 13;11(24):4026. doi: 10.3390/cells11244026. Cells. 2022. PMID: 36552790 Free PMC article.
Metabolic changes during prostate cancer development and progression.
Beier AK, Puhr M, Stope MB, Thomas C, Erb HHH. Beier AK, et al. Among authors: puhr m. J Cancer Res Clin Oncol. 2023 May;149(5):2259-2270. doi: 10.1007/s00432-022-04371-w. Epub 2022 Sep 23. J Cancer Res Clin Oncol. 2023. PMID: 36151426 Free PMC article. Review.
Toll-Like Receptor 3 Overexpression Induces Invasion of Prostate Cancer Cells, whereas Its Activation Triggers Apoptosis.
Muresan XM, Slabáková E, Procházková J, Drápela S, Fedr R, Pícková M, Vacek O, Víchová R, Suchánková T, Bouchal J, Kürfürstová D, Král M, Hulínová T, Sýkora RP, Študent V, Hejret V, van Weerden WM, Puhr M, Pustka V, Potěšil D, Zdráhal Z, Culig Z, Souček K. Muresan XM, et al. Among authors: puhr m. Am J Pathol. 2022 Sep;192(9):1321-1335. doi: 10.1016/j.ajpath.2022.05.009. Epub 2022 Jun 22. Am J Pathol. 2022. PMID: 35750257 Free article.
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Csizmarik A, Keresztes D, Nagy N, Bracht T, Sitek B, Witzke K, Puhr M, Tornyi I, Lázár J, Takács L, Kramer G, Sevcenco S, Maj-Hes A, Jurányi Z, Hadaschik B, Nyirády P, Szarvas T. Csizmarik A, et al. Among authors: puhr m. Int J Cancer. 2022 Oct 15;151(8):1405-1419. doi: 10.1002/ijc.34159. Epub 2022 Jun 21. Int J Cancer. 2022. PMID: 35689436 Free PMC article.
47 results